Literature DB >> 22775209

Targeted gene delivery to hepatocytes with galactosylated amphiphilic cyclodextrins.

Anthony McMahon1, Martin J O'Neill, Eva Gomez, Ruth Donohue, Damien Forde, Raphael Darcy, Caitriona M O'Driscoll.   

Abstract

OBJECTIVES: Achieving targeted delivery of gene medicines is desirable to maximise activity. Here, galactosylated amphiphilic cyclodextrins (CDs) are examined in terms of their ability to transfect asialoglycoprotein receptor-bearing HepG2 cells.
METHODS: Cationic amphiphilic CDs were synthesised as well as amphiphilic CDs bearing galactose-targeting ligands with different linker lengths. Binding of galactosylated CDs to a galactose-specific lectin was examined by surface plasmon resonance. CDs were formulated with and without the helper lipid DOPE and complexed with plasmid DNA. Transfection was evaluated by luciferase assay. Intracellular trafficking was assessed by confocal microscopy. KEY
FINDINGS: Binding of targeted CDs to a galactose-specific lectin was achieved. Binding decreased with linker length between the galactosyl group and the CD core. Contrary to the lectin binding results, transfection levels increased with an increase in linker length from 7 atoms to 15. Compared to non-targeted formulations, a significant increase in transfection was observed only in the presence of the helper lipid DOPE. Confocal microscopy revealed that DOPE caused a pronounced effect on cellular distribution.
CONCLUSIONS: The galactose-targeting ligand induced substantial increases in transfection over non-targeted formulations when DOPE was included, indicating the potential for targeted gene delivery using CD-based delivery systems.
© 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22775209     DOI: 10.1111/j.2042-7158.2012.01497.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Diagnosis of abnormal biliary copper excretion by positron emission tomography with targeting of (64)Copper-asialofetuin complex in LEC rat model of Wilson's disease.

Authors:  Ralf Bahde; Sorabh Kapoor; Kuldeep K Bhargava; Christopher J Palestro; Sanjeev Gupta
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

2.  Click-modified cyclodextrins as nonviral vectors for neuronal siRNA delivery.

Authors:  A M O'Mahony; B M D C Godinho; J Ogier; M Devocelle; R Darcy; J F Cryan; C M O'Driscoll
Journal:  ACS Chem Neurosci       Date:  2012-08-03       Impact factor: 4.418

3.  In vitro investigations of the efficacy of cyclodextrin-siRNA complexes modified with lipid-PEG-Octaarginine: towards a formulation strategy for non-viral neuronal siRNA delivery.

Authors:  Aoife M O'Mahony; Stephane Desgranges; Julien Ogier; Aoife Quinlan; Marc Devocelle; Raphael Darcy; John F Cryan; Caitriona M O'Driscoll
Journal:  Pharm Res       Date:  2012-11-29       Impact factor: 4.200

4.  Cationic and PEGylated Amphiphilic Cyclodextrins: Co-Formulation Opportunities for Neuronal Sirna Delivery.

Authors:  Aoife M O'Mahony; Julien Ogier; Raphael Darcy; John F Cryan; Caitriona M O'Driscoll
Journal:  PLoS One       Date:  2013-06-21       Impact factor: 3.240

Review 5.  Gene delivery based on macrocyclic amphiphiles.

Authors:  Wen-Chao Geng; Qiaoxian Huang; Zhe Xu; Ruibing Wang; Dong-Sheng Guo
Journal:  Theranostics       Date:  2019-05-18       Impact factor: 11.556

6.  A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer.

Authors:  Dandan Sun; Yifang Zou; Liu Song; Shulan Han; Hao Yang; Di Chu; Yun Dai; Jie Ma; Caitriona M O'Driscoll; Zhuo Yu; Jianfeng Guo
Journal:  Acta Pharm Sin B       Date:  2021-06-18       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.